No products in the cart.
Pre-made Praluzatamab benchmark antibody ( Whole mAb, anti-CD166/ALCAM therapeutic antibody, Anti-MEMD Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-454
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Praluzatamab biosimilar, Whole mAb, Anti-CD166/ALCAM Antibody: Anti-MEMD therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Praluzatamab Ravtansine is a probody-drug conjugate (PDC) composed of a recombinant antibody targeting the tumor-associated antigen (TAA) CD166, which is masked by a cleavable masking peptide, and conjugated to the cytotoxic agent maytansinoid DM4, with potential antineoplastic activity.
| Products Name (INN Index) | Pre-Made Praluzatamab biosimilar, Whole mAb, Anti-CD166/ALCAM Antibody: Anti-MEMD therapeutic antibody |
|---|---|
| INN Name | Praluzatamab |
| Target | ALCAM |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | CytomX Therapeutics,Immunogen |
| Conditions Approved | NA |
| Conditions Active | Solid tumours |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD166 |
| Package |
Previous slide
Next slide
